Two Long-Established Independent IRBs Discussing Merger
Independent Review Consulting (IRC) an independent Institutional Review Board (IRB) founded in 1984 announced that it has entered into a preliminary agreement to merge with the Ethical Review Committee (ERC), another central IRB providing reviews of research on behalf of subject safety since 1988. Erica Heath, founder of Independent Review Consulting (IRC), accredited by the Association for the Accreditation of Human Research Protection Program, Inc. (AAHRPP) and located in Northern California is in talks with Terri Majors, President of the Ethical Review Committee (ERC) in Missouri. Under the terms of the proposed merger, the two organizations will begin implementing an integration plan immediately while they continue to operate as their respective organizations. The first phase of the plan will be the formation of Ethical and Independent Review Services (E&I), a new Limited Liability Corporation to provide management services for both entities. Both companies have experience in the review of late-stage, multi- center trials. While IRC specializes in medical devices and federally funded studies, ERC has developed processes specializing in efficient turn-around of large, late-stage multi-center trials.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
